162 related articles for article (PubMed ID: 19794937)
1. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
Yoon JS; Kim JC; Lee SY
Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
Sane S; Ali MJ; Naik MN
Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
Nüssgens Z; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
[TBL] [Abstract][Full Text] [Related]
5. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
Lee S; Park S; Lew H
Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
9. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
10. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
[TBL] [Abstract][Full Text] [Related]
11. Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?
Pang AL; O'Day J
Clin Exp Ophthalmol; 2006 Jul; 34(5):441-4. PubMed ID: 16872340
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
Rieder CR; Schestatsky P; Socal MP; Monte TL; Fricke D; Costa J; Picon PD
Clin Neuropharmacol; 2007; 30(1):39-42. PubMed ID: 17272968
[TBL] [Abstract][Full Text] [Related]
13. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
[TBL] [Abstract][Full Text] [Related]
15. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Saad J; Gourdeau A
J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
Jankovic J
Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
[TBL] [Abstract][Full Text] [Related]
17. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
19. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
20. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]